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Background/aim: Vascular calcifications (VCs), recognized risk factor for increased mortality, are highly prevalent in hemodialysis
(HD) patients. We aimed to investigate the relation between VC and warfarin use with plain radiography.
Materials and methods: VCs were assessed using Adragao (radial and digital) and Kauppila (aortic) scores in 76 HD patients from six
centers. Out of a total 711 HD patients, there were 32 (4.5%) who had been treated with warfarin for at least 1 year, and we included 44
control patients.
Results: Of the patients, 47% were females, the mean age was 66 ± 9 years, 23% were diabetics, the mean dialysis vintage was 68 ± 38
months. In warfarin group, median Kauppila score was higher than in control group [11 vs 6.5, (25%–75% percentile, 5 vs. 15), p =
0.032] and the percentage of the patients with a Kauppila score of >6 was higher, as well (76.6% vs. 50%; p = 0.029). Median Adragao
score was not significantly different between the two groups [7 vs. 6, (%25,%75 percentile 6 vs. 8), p = 0.17]. Logistic regression analysis
revealed that warfarin treatment was independently associated with Kauppila scores of >6 (OR 3.60, 95% CI 1.18–10.9, p = 0.024).
Conclusion: In this study, we found that warfarin is associated to vascular calcifications, especially in aorta of HD patients.
Key words: Hemodialysis, vascular calcification, vitamin K, warfarin

1. Introduction
Vascular calcification (VC) is a pathological mineralization
process occuring mainly in elastic and muscular arteries
such as aorta, iliac, coronary and peripheral arteries. VCs
are highly prevalent and related to increased mortality
in end-stage kidney diseases [1]. VC is an active cellular
process and occurs as a result of the promoters for
calcification overwhelming the inhibitors. Matrix Gla
Protein (MGP), a molecule secreted by chondrocytes
and vascular smooth muscle cells, is the most significant
known natural calcification inhibitor, and it needs Vitamin
K-dependent carboxylation and phosphorylation in order
to be active [2]. Warfarin is an old drug that exerts its
anticoagulant effects by blocking the γ-carboxylation of
coagulation factors, resulting, therefore, in the inhibition
of the activation of other vitamin K-dependent proteins.
It was shown in mice models that treatments with vitamin
K antagonists resulted in increased VC, both in mice with
chronic kidney disease (CKD) and in those with normal

renal function [3,4]. This also holds true for humans:
the patients that are treated with warfarin are facing an
increased VC compared to those who are not treated
with vitamin K antagonists [5,6]. CKD patients are prone
to developing VCs because they have a defective uremic
and hyperphosphatemic balance [7]. Medial artery
calcifications that seem to be more related to mineral
metabolism changes have been considered separately from
intimal calcifications of common atherosclerosis [8].
Warfarin has been prescribed in dialysis patients for a
long time and continues to be so, as there is not enough data
about new oral anticogulants in CKD [9]. Additionally,
Vitamin K deficiency–related clinical consequences and
their treatments have been investigated in recent years
[10,11]. Although the evidences are circumstantial since
the number of patients using warfarin is relatively low, and
there are other mechanisms causing vascular calcifications
in HD patients; warfarin and VC have nonetheless been
known to be related [12,13]. The use of plain radiography
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of the abdominal aorta (Kauppila score) and/or the hands
and pelvis (Adragao score) to rate vascular calcifications
has been validated by various studies both in dialysis
and predialysis patients. These studies also have a good
correlation with coronary calcifications and mortality
[14–16].
The aim of this study is to investigate the relationship
between VC and warfarin use in hemodialysis patients
and to emphasize the ease of revealing a VC with a simple
method in order to prevent it from progressing further.
2. Materials and methods
This is a cross-sectional, observational, case-control study
of prevalent hemodialysis (HD) patients from six centers.
This study was approved by Ankara University School of
Medicine Ethics Committee for Clinical Studies (Approval
Number: 10-798-19), and all the procedures were conducted
in accordance with the Declaration of Helsinki. From the
six hemodialysis centers, we included adult patients with
their informed consent who had been on dialysis for >1
year. The patients who had been on warfarin at least 1 year
were placed in study group. Out of a total 711 hemodialysis
patients, there were 32 (4.5%) who had been treated
with warfarin and we included, in the study, 44 random
control HD patients with matching parameters of age, sex,
comorbidities and dialysis vintage from the same centers
as the aforementioned warfarin–treated patients (Table 1).
After specifying the possible matched control patients in
the same center and same dialysis session, the responsible
doctors of each center randomly determined one or two
control patients. Power analysis showed that a minimum
sample size of 52 achieves 95% power to detect an effect size
of 0.5 with a significance level of 0.05. In total, we included
76 patients to the study. All 76 patients had been treated
with three-times-a-week hifg-flux HD and warfarin-treated
patients had been receiving warfarin for at least 1 year.
Lateral abdominal radiography (includes all lumbar
regions of the spinal column), frontal pelvic radiography,
and radiography of both hands were done in July 2019.
Femoral, iliac, digital and radial artery, and aortic vascular
calcifications were assessed using Adragao (AS; pelvis and
hands; min-max: 0-8) and Kauppila (KS; lateral lumbar
spine; min-max: 0-24) scores outlined below as described
in the literature. Pelvis films were divided into four
sections by a horizontal line over the upper limit of both
femoral heads and a median vertical line over the vertebral
column. (Figure 1.) A horizontal line divided the films of
each hand over the upper limit of the metacarpal bones.
(Figure 2.) The presence of vascular calcifications in each
section was rated as 1, and its absence as 0. Only linear
calcifications that outline the vessel wall were considered
as VC.
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The lateral abdominal radiographs were assessed
separately for each lumbar vertebra for the posterior
and anterior wall of the aorta using the midpoint of the
intervertebral space above and below the vertebrae as the
boundaries. (Figure 3.) The presence of small, scattered
calcific deposits was rated 1 if they filled less than one-third
of the longitudinal wall of the aorta; 2 if they filled less
than two-thirds of; 3 if they filled two-thirds or more of it,
and 0 if they were absent [16,17]. One single experienced
radiologist blinded to patient information performed the
analysis of all the radiographic films.
Data regarding the demographic characteristics,
duration of dialysis, duration of warfarin usage, dialysis
adequacy parameters including Kt/V (K:dialyzer clearance
of urea, t: dialysis time, V: volume of distribution of urea,
approximately equal to patient’s total body water) and urea
reduction ratio (URR), dialysis vascular access, blood
pressure measurement records, residual renal function
(intradialytic urine output >300 mL/day), concomitant
treatments, laboratory results, and possible risk factors
related to VC were recorded based on the records in 6
months preceding vascular calcification score evaluation.
Calcium, phosphorus, hemoglobin, albumin, URR, and
Kt/V were evaluated every month and serum PTH and
C-reactive protein every 3 months. Blood pressure (BP)
measurements were recorded before and after the midweek dialysis session, during the same 6 months period.
2.1. Statistical analysis
Clinical and laboratory data are expressed as percentages,
means (± SD) or medians [interquartile range (IQR)], as
appropriate. Continuous variables in the characteristics of
the two groups were compared by t-test or Mann–Whitney
U test, and categorical variables with Pearson’s chisquare or Fischer exact tests. Logistic regression analyses
were performed to study associations between vascular
calcification scores (dependent variable) and predictor
variables. Parameters with a <0.2 p-value in univariate
analysis were considered for entry in the multiple
logistic regression model along with the clinical-related
parameters. The final model was reached by backward
stepwise regression (Backward LR) method incorporating
constant. The quality of adjustment of the model was
tested with the Hosmer–Lemeshow statistic. Odds ratios
were expressed with 95% confidence intervals (CI). A
threshold value of p<0.05 was considered as statistically
significant. The calculations were made with IBM SPSS 23
(IBM SPSS v.23, Armonk, NY, USA).
3. Results
The average age of the participants was 66 ± 9 years, and
47% of them were females. Of the patients, 23% were
diabetics, the mean dialysis vintage was 68 ± 38 months,
and the mean Kt/V 1.66 ± 0.27. Out of a total of 76 patients,
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Table 1. Basic characteristics of the patients and summary of the results.
Parameter

Warfarin (+) n = 32

Warfarin (-) n = 44

p value

Age (years, mean±SD)

67.6 ± 9

64.54 ± 8

0.143

Female/Male

14, 43% / 18; 56%

22, 50% / 22, 50%

0.646

Diabetes mellitus +/- (n,%)

6, 18%

12, %27

0.427

Dialysis vintage (months, mean ± SD)

74.9 ± 44

63.6 ± 33

0.209

Kt/V

1.62 ± 0.2

1.7 ± 0.2

0.205

Warfarin usage time (months, mean±SD)

65.9 ± 43

NA

NA

Kauppila score (median, min-max)

11 (1-24)

6.5 (1-20)

0.032

Kauppila score > 6 (n, %)

23, 76.6%

22, 50%

0.029

Adragao score (median, min-max)

7 (2-8)

6 (0-8)

0.177

Adragao score ≥ 3 (n, %)

30, 93.7%

41, 93.1%

0.638

Vascular access
· Fistula (n,%)
· Central vein catheter (n,%)

23, 71.9%
9, 28.1%

43, 97%
1, 3%

0.001

Medical treatments (n,%)
· Ca-containing P-binder
· Non-Ca-containing P-binder
· Calcimimetics
· Active vitamin D
· IV iron
· ESA
· Antiaggregant

13, 40%
15, 46%
5, 15%
20, 62%
22, 68%
21, 65%
6, 18%

14, 31%
26, 59%
14, 31%
29, 65%
31, 70%
30, 68%
26, 59%

0.473
0.354
0.179
0.811
1.0
1.0
<0.001

Systolic blood pressure (mean±SD) (mmHg)

115.9 ±16.4

120.7 ± 23.1

0.319

Diastolic blood pressure (mean±SD) (mmHg)

67.5 ± 7.47

68.9 ± 12.69

0.540

Residual renal function (n, %)

13, 40%

14, 31%

0.473

Dialysate calcium ≥ 1.50 mmol/L (n,%)

14, 43.7%

15, 31.8%

0.475

Serum calcium (mg/dL) (mean±SD)

8.82 ± 0.5

8.78 ± 0.5

0.778

Serum phosphorus (mg/dL) (mean±SD)

4.62 ± 0.87

4.84 ± 0.89

0.279

Serum parathyroid hormone (pg/mL) (mean±SD)

376.23 ± 192.8

457.36 ± 251.2

0.116

Serum albumin (g/dL) (mean±SD)

3.81 ± 0.38

3.91 ± 0.52

0.361

Serum hemoglobin (g/dL) (mean±SD)

11.43 ± 1.1

11.6 ± 1.57

0.595

Serum C-reactive protein (mg/L) (mean±SD)

14.3 ± 12.2

13.8 ± 15.4

0.881

Serum LDL cholesterol (mg/dL) (mean± SD)

106.8 ± 41

107 ± 34

0.966

Serum HDL cholesterol (mg/dL) (mean± SD)

37.1 ± 10

38.9 ± 7

0.384

Serum triglyceride (mg/dL) (mean±SD)

158.9 ± 77

175.7 ± 89

0.374

Abbreviations: Ca, Calcium; ESA, erythrocyte stimulant agents; HDL, high density protein; IV, intravenous; Kt/V,
K:dialyzer clearance of urea, t: dialysis time, V: volume of distribution of urea, approximately equal to patient’s total body
water; LDL, low density protein; P, phosphorus; SD, standart deviation.

while 45 (60.8%) had an increased Kauppila score (median
8, min 1- max 24); 71 (94.7%) had an increased Adragao
score (median 6, min 0- max 8).
In the study, we included patients who had been taking
warfarin for at least one year. Their mean duration of
warfarin treatment was 65.9 ± 43 months, and median
weekly dosage of warfarin was 25 mg (min 7.5 mg- max

40 mg). Warfarin indications were atrial fibrillation (n =
16), heart valve replacement (n = 9), recurrent pulmonary
thromboembolism (n = 5), and recurrent deep venous
thromboembolism (n = 2).
In warfarin group, median Kauppila score was higher
than in control group [11 vs 6.5, p = 0.032] and the
percentages of the patients with a Kauppila score of >6
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Figure 1. Pelvis graphy- iliac and femoral arterial calcifications.

Figure 2. Hand graphy- radial and digital arterial calcifications.
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Figure 3. Lateral abdominal graphy- aortic calcifications.

was higher, as well (76,6% vs. 50%; p = 0.029). Median
Adragao score was not significantly different between the
two groups [7 vs. 6, p = 0.177] (Table 1).
There were no significant differences detected in the
clinical characteristics and basic laboratory results between
control and warfarin group, except for vascular access
(Table 1). In warfarin group, there were 9 patients (28.1%)
with a central venous catheter, while there was only 1 such
patient (3%) in control group. Considering the possible
effects on vascular calcification, concomitant medications,
including calcium-containing and noncalcium-containing
phosphate binders, calcimimetics, vitamin D, dialysate
calcium concentrations were recorded. There was no
significant difference in the percentage of patients who

have taken these medications. The only detail was that
there were fewer patients taking antiaggregant agents such
as aspirin or clopidogrel in warfarin group. There was also
no difference in the basic laboratory results between the
two groups.
To determine the independent risk factors for
vascular calcification, we conducted logistic regression
analysis. Age, warfarin treatment, serum parathormone,
serum calcium, serum phosphorus, dialysis vintage were
considered as possible independent risk factors for the
reason that their p-values were <0.20 in univariate analysis
or for their clinical relevance of vascular calcification. We
conducted a multivariate analysis with these 6 possible
variables and at last step of logistic regression analysis
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Table 2. Multivariate analysis results for the risk factors for Kauppila score >6.
Univariate

Multivariate *

Parameter

p-value

Odds ratio (95% CI)

P value

Odds ratio (95% CI)

Warfarin

0.024

3.28 (1.17–9.22)

0.024

3.60 (1.18–10.97)

Age

0.192

1.03 (0.98–1.09)

NS

Serum parathormone level (pg/mL)

0.651

1 (0.99–1.0)

NS

Serum calcium level (mg/dL)

0.961

1.02 (0.41–2.49)

NS

Serum phosphorus level (mg/dL)

0.964

0.988 (0.58–1.66)

NS

Dialysis vintage (months)

0.785

1.00 (0.99–1.01)

NS

Abbreviations: CI, confidence interval; NS, not significant.
*Final step of logistic regression analysis using Backward LR method.

model, it was revealed that only the warfarin treatment was
associated with Kauppila scores of >6 (OR 3.28, 95% CI
1.17-9.22, p = 0.024) (Table 2). Although Adragao scores
were not different between warfarin and control groups, we
checked for the same risk factors for an Adragao score of
≥3; however, we were not able to find a significant relation.
4. Discussion
This study revealed that vascular calcification is observed
in almost all dialysis patients, and that warfarin is a strong
risk factor for vascular calcifications, especially in aorta
of hemodialysis patients. We found that the presence of
VC assessed by plain radiographies of the abdominal
aorta is more frequent and severe probably because of the
deleterious effects of warfarin on the vessels in patients who
have been receiving warfarin for over a year. This is a direct
study with relatively sufficient number of patients using
warfarin, and it reveals that warfarin might accelerates the
vascular calcifications in HD patients.
The mechanism of increased vascular calcification as
a result of warfarin is presumably related to insufficient
activation of MGP. There is evidence that the inactive
form of MGP reflects vitamin K-deficiency as a result of
warfarin treatment, and this is associated with medial
arterial calcification in HD patients [18]. In addition, they
showed decreased dephosphorylated-undercarboxylated
MGP (dp-ucMGP) after Vitamin K supplementation [19].
Tantisattamo et al. compared the screening mammograms
in patients who had been treated with and without
warfarin and showed that, even in non-renal population,
warfarin treatment is associated with increased VC [4].
Additionally, they indicated that the prevalence of VC
increased even more with a longer treatment duration,
especially >6 months. Arterial wall properties change with
advanced age; however, the prevalence of VC increases
with the advancing stage of CKD even in young patients
in whom medial calcification was found to be more
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prevalent than intimal calcification and to be related to
cardiovascular mortality [20,21]. To avoid such a conflict,
we only included the patients who had been receiving
warfarin for at least 1 year, and we compared them with
the patients matching for age, sex, diabetes mellitus, and
dialysis vintage.
The diagnosis of vascular calcification has been made
with expensive and technical devices such as multislice
computed tomography [22]; however, plain radiographic
films are practical, inexpensive, and they correlate with
advanced techniques [23]. Plain films are also suggested
in the KDIGO 2017 guidelines for the assessment of VC
in CKD [24]. Fusaro et al. [13] used lumbar graphies to
reveal aortic and iliac VC with a different assessment
method which interprets in centimeters the entirety of
the calcifications occuring only on one edge of the vessel
[25], and they still found the same relation between
VC and warfarin. Recently, the Valkyrie Study [12],
a randomized controlled trial, has tested the effect of
warfarin, rivaroxaban and vitamin K2 supplementation
on VC progression detected by computed tomography of
the heart and thoracic aorta in hemodialysis patients with
atrial fibrillation. They did not find a difference in the VC
progression despite a significant decrease in dp-ucMGP
levels. Their study population consisted mostly of prevalent
hemodialysis patients who had been taking warfarin at the
inclusion of the study, and they only evaluated the thoracic
part of the aorta for VC.
The presence of VC may be heterogeneous, such as
classical atherosclerosis in the context of aorta; medial
calcification, in the context of muscular arteries, cardiac
valve calcifications; and calciphylaxis. While common
atherosclerotic process is linked to inflammation,
dyslipidemia or advance age, medial calcification seems
to be more related to bone-mineral disorders or CKD.
Mourad et al. [26] tried to prove this phenomenon by
measuring the elevated stiffness and the diameter of radial
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arteries of end-stage renal disease (ESRD) patients and
comparing them to control groups. They indicated that
muscular arterial wall alterations should be related to the
ESRD status, and not to blood pressure changes.
Adragao et al. [15] identified a simple score evaluating
iliac, femoral, radial and digital arteries, and they found
that the cut-off value of ≥3 is the best association with
cardiovascular morbidity and mortality. Kauppila et
al. [16] developed a score of calcification of abdominal
aorta based on the lateral abdominal films obtained from
Framingham heart study participants, and prominent VC
was scored as >6. Elevated Kauppila score is also shown
to be related to mortality in hemodialysis patients [27].
Gorriz et al. [14] used both scores in their study with nondialysis CKD patients, and they found an Adragao score of
≥3 (but not a Kauppila score of >6) that is independently
associated with all-cause and cardiovascular mortality.
Additionally, age, phosphorus, and diabetes were found
to be related to Adragao score, which is consistent with
Mourad’s aforementioned study [26].
We used the same validated scores because they are
very simple and easy to use and may help distinguish the
high risk patients earlier. In our study, the percentages of
the patients with an Adragao score of ≥3 were 93.7% and
93.1%, and those with a Kauppila score of >6 were 76.6%
and 50% in warfarin and control groups, respectively. It
is probably related to the capacity of Kauppila score that
allows it to show calcifications in a wider range of intensity
as a Kauppila score would rate a given region as 0–3, as
opposed to an Adragao score, which would rate it as 0–1
for an artery. We found that increased aortic calcification
is associated with warfarin usage; however, we could not
show the difference in peripheral and iliofemoral arteries
(Adragao scores) because it had already increased in
almost all the patients in both groups.
Although hyperphosphatemia has been associated
with VC [28], Adragao et al. [17] found no correlation
between total VC scores and calcium, phosphate or
PTH levels in their study. Choi et al. [29] concluded that
hypoalbuminemia, high CRP, low LDL-cholesterol, and
the presence of baseline calcification in aorta were found to
be significant risk factors for the progression of abdominal
aortic calcification, which was assessed by lateral
abdominal radiography. In some studies, it is suggested
that cinacalcet might reduce vascular calcification [30]. In
our study, however, there was no difference between the
two groups in terms of concomitant drugs, electrolytes,
PTH, CRP, anemia or lipid status. Additionally, in logistic

regression analysis, we took into account the age, warfarin
treatment, serum parathormone, serum calcium, serum
phosphorus, and dialysis vintage as risk factors and only
warfarin was independently associated with abdominal
aortic calcifications.
There is conflicted data regarding the benefit of
using warfarin in dialysis patients in order to prevent
cerebrovascular events in patients with atrial fibrillation
[31]. Given the fact that these patients are more prone to
cardiovascular diseases, it seems prudent to restrict the
wide prescription of warfarin at least for atrial fibrillation
in dialysis patients. Recently, apixaban has been approved
for use in patients with atrial fibrillation and ESRD in USA
[32], and it may become a solution to this conflict.
Our study has some limitations. The small number
of patients may influence the statistical significances.
Although we had a matching control group, we did not
have the chance to assess initial Adragao and Kauppila
scores at the beginning of warfarin treatment. In terms
of matching differences, antiaggregant agent usage was
lower in warfarin group; this probably reflected the
intention of preventing further bleeding complications.
The cross-sectional nature of our study did not allow
the identification of all the factors associated with VC
progression and/or mortality. We did not measure the dpucMGP levels, which is an accurate biomarker for vascular
vitamin K stores.
In conclusion, based on our results, long-term warfarin
treatment is associated with vascular calcification, and
it should be used with extreme caution in hemodialysis
patients.
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